Information about Vardenafil
Vardenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction.
Liver safety of Vardenafil
Vardenafil has not been associated with serum aminotransferase elevations nor with clinically apparent liver injury.
Mechanism of action of Vardenafil
Vardenafil (var den' a fil) is a selective inhibitor of phosphodiesterase type 5 (PDE5), an intracellular enzyme that mediates the breakdown of cyclic guanosine monophosphate (cGMP) inducing smooth muscle relaxation in the corpus cavernosum of the penis and in the pulmonary vasculature where this specific phosphodiesterase is found.
FDA approval information for Vardenafil
Vardenafil is effective in prolonging erection and was approved for use in the United States in 2003.
Dosage and administration for Vardenafil
Vardenafil is available in tablets of 2.5, 5, 10 and 20 mg under the brand name of Levitra and as 10 mg oral disintegrating tablets under the brand name of Staxyn. The recommended dose is 10 mg as a single dose as needed one hour before sexual activity. The dose of the standard oral tablet can be increased or decreased based upon effect and tolerance, with a recommended maximum frequency of once daily and maximum dosage of 20 mg.
Side effects of Vardenafil
Common side effects include dizziness, headache, flushing, hypotension, rhinitis and dyspepsia. Rare, but potentially serious adverse events include vision and hearing loss, hypotension, cardiovascular events and priapism.
PDE 5 inhibitors